Research programme: retinal degeneration gene therapy - Amsterdam Molecular Therapeutics
Latest Information Update: 24 Sep 2009
At a glance
- Originator Amsterdam Molecular Therapeutics
- Class Gene therapies; Targeted gene repair
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 31 Dec 2008 Discontinued - Preclinical for Eye disorders in Netherlands (Ophthalmic)
- 24 Mar 2006 Preclinical trials in Eye disorders in the Netherlands (unspecified route)